Skip to main content

Table 4 Multivariate cox analyses of biomarkers and clinical factors with OS

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

  High-grade serous carcinoma Clear cell carcinoma
Factors Hazard Ratio (95% CI) HGSC P Hazard Ratio (95% CI) CCC P
Stage
 Early(I + II) 1.000   1.000  
 Late(III + IV) 3.320(0.965–11.427) 0.057 9.703(2.588–36.381) 0.001
Residual tumor
  < 1 cm 1.000   1.000  
  > 1 cm 1.367(0.560–3.339) 0.492 1.400(0.244–8.032) 0.706
Ascites
 No 1.000   1.000  
 Yes 0.994(0.293–3.373) 0.993 2.587(0.848–7.890) 0.095
Chemotherapeutic response
 Sensitive 1.000   1.000  
 Resistant 3.803(2.170–6.664) 0.000 3.562(1.063–11.936) 0.040
EGFR
 Negative 1.000   1.000  
 Positive 1.244(0.653–2.370) 0.507 0.044(0.003–0628) 0.021
HER2
 Negative 1.000   1.000  
 Positive 1.277(0.299–5.456) 0.741 7.948(1.745–36.208) 0.007
PTEN
 Negative 1.000   1.000  
 Positive 0.696(0.257–1.880) 0.474 4.475(0.825–24.274) 0.082
AURKA
 Negative 1.000   1.000  
 Positive 2.082(1.162–3.730) 0.014 1.763(0.616–5.044) 0.291
BRCA1
 Negative 1.000   1.000  
 Positive 0.433(0.211–0.885) 0.022 1.934(0.653–5.738) 0.235
BRCA2
 Negative 1.000   1.000  
 Positive 1.671(0.755–3.701) 0.206 1.258(0.352–4.493) 0.723
PD-L1
 Negative 1.000   1.000  
 Positive 0.520(0.182–1.487) 0.222 1.157(0.387–3.456) 0.794
  1. CI confidence interval
  2. Bold value denotes P with statistical significance